A subcutaneous polymeric opioid delivery system for the treatment of cancer pain

Stuart A. Grossman; Suzanne Nesbit

doi:10.1016/j.eujps.2010.09.009

A subcutaneous polymeric opioid delivery system for the treatment of cancer pain

Stuart A. Grossman, Suzanne Nesbit

Johns Hopkins Hospital

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The optimal control of pain related to cancer requires the use of potent opioid analgesics. Despite significant efforts by the World Health Organization and other international agencies, oral morphine and other opioids remain largely unavailable to 80% of the world's population. As more cancer cases are being diagnosed in the developing world than elsewhere, large numbers of patients worldwide suffer from cancer-related pain without reasonable therapeutic options. This manuscript describes a polymeric opioid delivery system designed to provide opioids subcutaneously at a continuous rate for 1-3. months alleviating concerns regarding compliance, misuse, diversion and costs. This approach to opioid administration could substantially impact the global treatment of patients with cancer pain.

Original language	English (US)
Pages (from-to)	257-259
Number of pages	3
Journal	European Journal of Pain Supplements
Volume	4
Issue number	4
DOIs	https://doi.org/10.1016/j.eujps.2010.09.009
State	Published - Nov 2010

Keywords

Cancer pain
Developing nations
Hydromorphone
Implant
Opioids
Polymer
Subcutaneous

ASJC Scopus subject areas

Anesthesiology and Pain Medicine

Access to Document

10.1016/j.eujps.2010.09.009

Cite this

@article{b4a5c8544bbe4f8da09d716327b7520b,

title = "A subcutaneous polymeric opioid delivery system for the treatment of cancer pain",

abstract = "The optimal control of pain related to cancer requires the use of potent opioid analgesics. Despite significant efforts by the World Health Organization and other international agencies, oral morphine and other opioids remain largely unavailable to 80% of the world's population. As more cancer cases are being diagnosed in the developing world than elsewhere, large numbers of patients worldwide suffer from cancer-related pain without reasonable therapeutic options. This manuscript describes a polymeric opioid delivery system designed to provide opioids subcutaneously at a continuous rate for 1-3. months alleviating concerns regarding compliance, misuse, diversion and costs. This approach to opioid administration could substantially impact the global treatment of patients with cancer pain.",

keywords = "Cancer pain, Developing nations, Hydromorphone, Implant, Opioids, Polymer, Subcutaneous",

author = "Grossman, {Stuart A.} and Suzanne Nesbit",

year = "2010",

month = nov,

doi = "10.1016/j.eujps.2010.09.009",

language = "English (US)",

volume = "4",

pages = "257--259",

journal = "European Journal of Pain Supplements",

issn = "1754-3207",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - A subcutaneous polymeric opioid delivery system for the treatment of cancer pain

AU - Grossman, Stuart A.

AU - Nesbit, Suzanne

PY - 2010/11

Y1 - 2010/11

N2 - The optimal control of pain related to cancer requires the use of potent opioid analgesics. Despite significant efforts by the World Health Organization and other international agencies, oral morphine and other opioids remain largely unavailable to 80% of the world's population. As more cancer cases are being diagnosed in the developing world than elsewhere, large numbers of patients worldwide suffer from cancer-related pain without reasonable therapeutic options. This manuscript describes a polymeric opioid delivery system designed to provide opioids subcutaneously at a continuous rate for 1-3. months alleviating concerns regarding compliance, misuse, diversion and costs. This approach to opioid administration could substantially impact the global treatment of patients with cancer pain.

AB - The optimal control of pain related to cancer requires the use of potent opioid analgesics. Despite significant efforts by the World Health Organization and other international agencies, oral morphine and other opioids remain largely unavailable to 80% of the world's population. As more cancer cases are being diagnosed in the developing world than elsewhere, large numbers of patients worldwide suffer from cancer-related pain without reasonable therapeutic options. This manuscript describes a polymeric opioid delivery system designed to provide opioids subcutaneously at a continuous rate for 1-3. months alleviating concerns regarding compliance, misuse, diversion and costs. This approach to opioid administration could substantially impact the global treatment of patients with cancer pain.

KW - Cancer pain

KW - Developing nations

KW - Hydromorphone

KW - Implant

KW - Opioids

KW - Polymer

KW - Subcutaneous

UR - http://www.scopus.com/inward/record.url?scp=78149361373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149361373&partnerID=8YFLogxK

U2 - 10.1016/j.eujps.2010.09.009

DO - 10.1016/j.eujps.2010.09.009

M3 - Article

AN - SCOPUS:78149361373

SN - 1754-3207

VL - 4

SP - 257

EP - 259

JO - European Journal of Pain Supplements

JF - European Journal of Pain Supplements

IS - 4

ER -

A subcutaneous polymeric opioid delivery system for the treatment of cancer pain

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this